Authors: Lim, A. G.¹; Walker, C.¹; Chambers, S.²; Gould, S. R.¹

Source: Alimentary Pharmacology & Therapeutics, Volume 11, Number 3, June 1997 , pp. 537-540(4)

Publisher: Wiley-Blackwell

Abstract:

Aim:

To evaluate the efficacy of a 7-day regimen of clarithromycin 250 mg b.d., amoxycillin 1 g b.d., and lansoprazole 30 mg b.d. as a treatment for Helicobacter pylori infection. Methods:

H. pylori status of dyspeptic patients was assessed by ¹³C-urea breath test and at endoscopy by histology, culture and rapid urease testing of gastric biopsies. Fifty-one H. pylori-positive patients were treated with the above regimen. H. pylori status was reassessed by ¹³C -urea breath test not less than 28 days after completing treatment. Adverse events and compliance were evaluated. Results:

On an intention-to-treat basis, H. pylori infection was cured in 77% (95% CI: 65-88%) of patients. Minor side-effects including diarrhoea, nausea and taste disturbance were reported by 64% of patients. Ninety-five per cent of patients consumed > 95% of tablets. Metronidazole resistance was 29% but all cultures were sensitive to amoxycillin and clarithromycin. Conclusion:

This 7-day treatment with low-dose clarithromycin was moderately effective in curing H. pylori infection. Although compliance was excellent, there was a high frequency of minor adverse events.

Document Type: Research article

DOI: http://dx.doi.org/10.1046/j.1365-2036.1997.00184.x

Affiliations: 1: Departments of Gastroenterology, Epsom Healthcare NHS Trust and PHLS Laboratory, Epsom, Surrey, UK 2: Departments of Microbiology, Epsom Healthcare NHS Trust and PHLS Laboratory, Epsom, Surrey, UK

Publication date: 1997-06-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Pathology ,  Pharmacology ,  Surgery ,  Therapeutics & Alternative Medicine
• By this author: Lim, A. G. ;  Walker, C. ;  Chambers, S. ;  Gould, S. R.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers